久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

US EUROPE AFRICA ASIA 中文
Business / Industries

Stem cells offer ray of hope for healthy future

By Alfred Romann in Seoul For China Daily (China Daily) Updated: 2014-06-23 07:08

Regenerative medicine sector needs more financial support from private investors

One of the most important and innovative pharmaceutical companies in Asia has its headquarters in a busy neighborhood of Seoul, nestled between insurance companies and banks, and not far from Seoul National University.

Medipost Co Ltd, launched in 2000 to research and develop stem cell and regenerative medicine products, has emerged as a leader in the space, both regionally and globally. It took a dozen years for the company to launch its first product commercially: Cartistem used to treat repair cartilages in the knee.

Between its founding and its first product launch, Medipost issued new shares six times and split its stock once. It generated some further revenue, mostly by storing umbilical cord blood, using the blood to transplant stem cells, and later by out-licensing products.

But that income was tiny compared to the cost of developing its drugs. Improbably, it managed to attract enough investors to keep going and growing.

That investment is now starting to pay off. Cartistem is just one of three stem cell products approved for sale in South Korea, and Medipost might be the only public company in the country with global ambitions.

"There are not many companies that can deal with global development in the pharmerging market," said Jay Lee, a senior director at Medipost, speaking at a conference in South Korea last month.

The "pharmerging" markets are the emerging markets for pharmaceutical products. China is possibly the biggest, but there are quite a few of them in the region including South Korea and much of the Association of Southeast Asian Nations.

Even Japan, despite its large economy, is considered an emerging market in some ways because it is often years before drugs developed elsewhere make their way down to patients there due to conservative regulations.

But much is changing in the region, particularly in South Korea and Japan. Both countries are embracing often-controversial research into regenerative medicine, including stem cells.

"There is an exceptional example of a new approach in Japan. They are looking very much, as in South Korea, to develop the stem cell space," says Dianne Jackson-Matthews, an Australia-based director at ERA Consulting Group.

For the time being, government support is driving the growth of this particular industry. Private or institutional investors are not yet convinced that taking a risk on a company developing a drug using science few people understand is worthwhile.

Stem cells offer ray of hope for healthy future

Stem cells offer ray of hope for healthy future

 Stem Cell Industrial Park under construction in Wenjiang  Medical experts call for effective stem cell treatment regulation

Previous Page 1 2 3 Next Page

Hot Topics

Editor's Picks
...
...
主站蜘蛛池模板: 手机亚洲第一页 | 日韩一级在线播放免费观看 | 亚洲精国产一区二区三区 | 男女男精品视频 | 欧美精品xx | 久草在线手机 | 久久中文字幕在线观看 | 久久久一级 | 日韩三级视频在线观看 | 一区二区三区四区视频在线观看 | 欧美一及片 | 亚洲成 人a影院青久在线观看 | 亚洲成a人片在线观看精品 亚洲成a人片在线观看中 | 一区不卡在线观看 | 亚洲特一级毛片 | 一级毛片在线播放免费 | 在线观看人成午夜影片 | 亚洲欧美一区二区三区在线 | 202z欧美成人 | 欧美日韩高清性色生活片 | 免费观看女人一摸全是水 | 久草手机在线播放 | 欧美在线视频一区二区 | 7m视频精品凹凸在线播放 | 国产精品第五页 | 中文字幕在线一区二区在线 | 国产99精品在线观看 | 香港激情黄三级在线视频 | 日本三级香港三级网站 | 久草资源网站 | 亚洲天堂伊人 | 国产首页精品 | 中文字幕一二区 | 亚洲第一页在线播放 | 黄色a一片 | 性欧美videos高清精品 | 久久亚洲人成国产精品 | 一本久综合久久爱 | 台湾三级在线播放 | 久草在线观看资源 | 免费播放欧美毛片欧美aaaaa |